BCC Research
BCC Research

Fresenius SE & Co. KGaA

Company Snapshot

Founded: 1912
Entity Type: Public
Employees: 176,486
Region: Europe
Revenue: $23,299.6 Millions
Revenue Year: 2024
Headquarter: Bad Homburg, Germany
Key Geographics: North America, Europe, Asia-Pacific, Latin America, Africa

Company Overview

Fresenius SE & Co. KGaA is a global healthcare group that provides critical products and services for treating and caring for critically and chronically ill patients. It offers a range of healthcare products, including Levothyroxine Sodium for Injection, a treatment for hypothyroidism, and Lodixanol Injection, USP, a contrast agent for diagnostic imaging. The company provides innovative solutions across various therapeutic areas, supporting patient care in chronic conditions and medical diagnostics. Fresenius operates in over 60 countries through its subsidiaries, and it also has an international distribution network and over 50 production sites.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Fresenius SE & Co. KGaA In Reports

Infusion Pumps and Devices: Technologies and Global Markets

Our detailed report on the Infusion Pumps and Devices Markets report includes global revenue ($ Million) for base year data of 2024, estimated year data of 2025, and forecasts through 2030.

Global Thyroid Gland Disorders: Diagnostics and Treatment Market

Our detailed report on the Thyroid Gland Disorder Market trends It includes global revenue ($ Million) for the base year of 2023 and estimated data for the forecast period 2024 through 2029.

Intravenous (IV) Therapy and Vein Access: Global Markets

BCC Research Report: Dive into intravenous therapy and vein access market report breaks down revenues, while sales figures are estimated for the five years from 2024 through 2029.

View All Reports

Fresenius SE & Co. KGaA In News

Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeat

MarketBeat - Apr 02, 2026

Fresenius SE & Co. KGaA: Michael Sen, buy - TradingView

TradingView - Apr 01, 2026

AlphaValue/Baader Europe Upgrades Fresenius SE to Buy, Trims PT - MarketScreener

MarketScreener - Apr 02, 2026

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band - Fresenius Medical Care

Fresenius Medical Care - Feb 24, 2026

Read All News

Applications/End User Industries

  • Healthcare
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

Contact

© 2025 BCC Research

Privacy Policy |Site Map|Terms & Conditions
AI Sentiment